Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Update

Bolt Biotherapeutics, Inc. (NASDAQ:BOLTGet Free Report) saw a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 1,960,000 shares, an increase of 12.6% from the February 29th total of 1,740,000 shares. Currently, 8.2% of the company’s shares are sold short. Based on an average daily volume of 125,500 shares, the days-to-cover ratio is presently 15.6 days.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Occudo Quantitative Strategies LP grew its stake in shares of Bolt Biotherapeutics by 19.5% during the second quarter. Occudo Quantitative Strategies LP now owns 30,816 shares of the company’s stock valued at $63,000 after acquiring an additional 5,028 shares in the last quarter. Northern Trust Corp grew its stake in shares of Bolt Biotherapeutics by 31.5% during the fourth quarter. Northern Trust Corp now owns 41,005 shares of the company’s stock valued at $46,000 after acquiring an additional 9,823 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Bolt Biotherapeutics by 13.0% during the first quarter. Bank of New York Mellon Corp now owns 91,293 shares of the company’s stock valued at $249,000 after acquiring an additional 10,475 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Bolt Biotherapeutics by 130.4% during the third quarter. Tower Research Capital LLC TRC now owns 18,537 shares of the company’s stock valued at $28,000 after acquiring an additional 10,492 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Bolt Biotherapeutics by 8.3% during the fourth quarter. Geode Capital Management LLC now owns 154,076 shares of the company’s stock valued at $200,000 after acquiring an additional 11,853 shares in the last quarter. 86.70% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of Bolt Biotherapeutics in a research note on Friday, March 22nd.

Get Our Latest Stock Analysis on Bolt Biotherapeutics

Bolt Biotherapeutics Trading Down 6.7 %

NASDAQ:BOLT opened at $1.40 on Wednesday. The business’s 50-day moving average is $1.17 and its two-hundred day moving average is $1.07. The company has a debt-to-equity ratio of 0.15, a current ratio of 5.17 and a quick ratio of 5.17. Bolt Biotherapeutics has a 12 month low of $0.84 and a 12 month high of $2.03. The firm has a market capitalization of $53.38 million, a PE ratio of -0.77 and a beta of 0.99.

About Bolt Biotherapeutics

(Get Free Report)

Bolt Biotherapeutics, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in Phase II clinical trial for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.

Featured Articles

Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.